DPP-4 inhibitors: DPP-4 inhibitors work by inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), which reduces the breakdown and inactivation of the incretin GLP-1 (glucagon-like peptide-1), leading to increased endogenous levels of GLP-1
Sample sizes were determined on the basis of previous experiments using similar methodologies
Rosenstock J, Hanefeld M, Shamanna P, et al
Currently, there is no established causal relationship between semaglutide and restless leg syndrome in the medical literature or FDA prescribing information
The review found that semaglutide and tirzepatide showed the highest reported rates of hair loss signals among GLP-1 therapies , with telogen effluvium and androgenetic alopecia being the most commonly reported hair-loss patterns
Obesity is a known risk factor for acid reflux, and the weight loss achieved through semaglutide treatment has, in some cases, led to a reduction in acid reflux symptoms